PERGAMON

Journal of Steroid Biochemistry & Molecular Biology 79 (2001) VI–VII

The Journal of
Steroid Biochemistry
&
Molecular Biology

www.elsevier.com/locate/jsbmb

Subject Index

Aromatase
alternations in hepatic expression of fatty-acid metabolising enzymes in, deficient (ArKO) mice and their reversal by treatment with 17β-estradiol or a peroxisome proliferator, 11
analysis of transcriptional regulation of human breast, 151
and COX-2 expression in human breast cancers, 41
bone phenotype of the, deficient mouse, 49
comparative approach to structure-function studies of mammalian, 289
deficient (ARKO) mice accumulate excess adipose tissue, 3
expression in male germ cells, 203
identification of the regulatory regions of the human, P450 (*CYP19*) gene involved in placenta-specific expression, 173
in atherosclerotic lesions of human aorta, 67
local endocrine effects of aromatase inhibitors within, 93
modulation of expression in human breast tissue, 35
molecular pharmacology of, and its regulation by endogenous and exogenous agents, 75
ovarian phenotype of the, knockout mouse (ArKO), 181
overexpression transgenic mice model, 27
peptide inhibition of cytokine-stimulated, activity in breast tissue fibroblasts, 165
phosphorylation processes mediate rapid changes of brain, activity, 261
potential role of estrogen in, regulation in the breast, 157
regulation of, activity in bone-derived cells: possible role of mitogen-activated protein kinase, 61
regulation of, by nuclear receptors, 187
role of, in endometrial disease, 19
tissue-specific expression of the human *CYP19*, gene in ovary and adipose tissue of transgenic mice, 193
Aromatase gene
characterization and purification of a protein binding to the *cis*-acting element for brain-specific exon 1 of the, in mouse, 255
Aromatase inhibitors
adjuvant trials of, determining the future landscape of adjuvant endocrine therapy, 133
biological and clinical effects of, in neoadjuvant therapy, 103
chemoprevention with, trial strategies, 143
comparative clinical pharmacology and pharmacokinetic interactions of, 85
local endocrine effects of, within the breast, 93
17α-methyl testosterone is a competitive, in JAR choriocarcinoma cells and macrophage-like TH1 cells in culture, 239
second-line randomized studies of, 109

Bone
phenotype of the aromatase deficient mouse, 49
regulation of aromatase activity in , -derived cells: possible role of mitogen- activated protein kinase, 61

Brain
characterization and purification of a protein binding to the *cis*-acting element for, -specific exon 1 of the mouse aromatase gene, 255
cytochrome P450 aromatase (*CYP19*) in, of non-human primate, 247
phosphorylation processes mediate rapid changes of aromatase activity in, 261
Breast cancer
adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in, patients, 115
a novel estrogen receptor downregulator: Faslodex (ICI 182,780) and its future possibilities in, 209
aromatase and COX-2 expression in human, 41
Breast tissue
analysis of transcriptional regulation of human, aromatase, 151
local endocrine effects of aromatase inhibitors within, 93
modulation of aromatase expression in human, 35
peptide inhibition of cytokine-stimulated aromatase activity in, fibroblasts, 165
potential role of estrogen in aromatase regulation in, 157

Cytochrome P450 aromatase
differential tissue distribution, developmental programming, estrogen regulation and promoter characteristics of, genes in teleost fish, 305
expression of the, encoding gene in cattle and sheep, 279
in the non-human primate brain, 247
phylogeny, expression, and enzyme activity of Zebrafish, genes, 299

Endometrial disease
role of aromatase in, 19
Endometrium
EM-652 (SCH57068) a pure SERM having complete antiestrogenic activity in the, 213
Estradiol
adaptive hypersensitivity to, and potential mechanism for secondary hormonal responses in breast cancer patients, 115
alternations in hepatic expression of fatty-acid metabolising enzymes in ArKO mice and their reversal by treatment with 17β-, 11
Estrogen(s)
stepwise, suppression manipulating the estrostat, 127

Faslodex (ICI 182,780)
a novel estrogen receptor downregulator: future possibilities in breast cancer, 209

PII: S0960-0760(01)00166-2

PERGAMON

Journal of Steroid Biochemistry & Molecular Biology 79 (2001) VI–VII

The Journal of
Steroid Biochemistry
&
Molecular Biology

www.elsevier.com/locate/jsbmb

Subject Index

Aromatase
alternations in hepatic expression of fatty-acid metabolising enzymes in, deficient (ArKO) mice and their reversal by treatment with 17β-estradiol or a peroxisome proliferator, 11
analysis of transcriptional regulation of human breast, 151
and COX-2 expression in human breast cancers, 41
bone phenotype of the, deficient mouse, 49
comparative approach to structure-function studies of mammalian, 289
deficient (ARKO) mice accumulate excess adipose tissue, 3
expression in male germ cells, 203
identification of the regulatory regions of the human, P450 (*CYP19*) gene involved in placenta-specific expression, 173
in atherosclerotic lesions of human aorta, 67
local endocrine effects of aromatase inhibitors within, 93
modulation of expression in human breast tissue, 35
molecular pharmacology of, and its regulation by endogenous and exogenous agents, 75
ovarian phenotype of the, knockout mouse (ArKO), 181
overexpression transgenic mice model, 27
peptide inhibition of cytokine-stimulated, activity in breast tissue fibroblasts, 165
phosphorylation processes mediate rapid changes of brain, activity, 261
potential role of estrogen in, regulation in the breast, 157
regulation of, activity in bone-derived cells: possible role of mitogen-activated protein kinase, 61
regulation of, by nuclear receptors, 187
role of, in endometrial disease, 19
tissue-specific expression of the human *CYP19*, gene in ovary and adipose tissue of transgenic mice, 193
Aromatase gene
characterization and purification of a protein binding to the *cis*-acting element for brain-specific exon 1 of the, in mouse, 255
Aromatase inhibitors
adjuvant trials of, determining the future landscape of adjuvant endocrine therapy, 133
biological and clinical effects of, in neoadjuvant therapy, 103
chemoprevention with, trial strategies, 143
comparative clinical pharmacology and pharmacokinetic interactions of, 85
local endocrine effects of, within the breast, 93
17α-methyl testosterone is a competitive, in JAR choriocarcinoma cells and macrophage-like TH1 cells in culture, 239
second-line randomized studies of, 109

Bone
phenotype of the aromatase deficient mouse, 49
regulation of aromatase activity in , -derived cells: possible role of mitogen- activated protein kinase, 61

Brain
characterization and purification of a protein binding to the *cis*-acting element for, -specific exon 1 of the mouse aromatase gene, 255
cytochrome P450 aromatase (*CYP19*) in, of non-human primate, 247
phosphorylation processes mediate rapid changes of aromatase activity in, 261
Breast cancer
adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in, patients, 115
a novel estrogen receptor downregulator: Faslodex (ICI 182,780) and its future possibilities in, 209
aromatase and COX-2 expression in human, 41
Breast tissue
analysis of transcriptional regulation of human, aromatase, 151
local endocrine effects of aromatase inhibitors within, 93
modulation of aromatase expression in human, 35
peptide inhibition of cytokine-stimulated aromatase activity in, fibroblasts, 165
potential role of estrogen in aromatase regulation in, 157

Cytochrome P450 aromatase
differential tissue distribution, developmental programming, estrogen regulation and promoter characteristics of, genes in teleost fish, 305
expression of the, encoding gene in cattle and sheep, 279
in the non-human primate brain, 247
phylogeny, expression, and enzyme activity of Zebrafish, genes, 299

Endometrial disease
role of aromatase in, 19
Endometrium
EM-652 (SCH57068) a pure SERM having complete antiestrogenic activity in the, 213
Estradiol
adaptive hypersensitivity to, and potential mechanism for secondary hormonal responses in breast cancer patients, 115
alternations in hepatic expression of fatty-acid metabolising enzymes in ArKO mice and their reversal by treatment with 17β-, 11
Estrogen(s)
stepwise, suppression manipulating the estrostat, 127

Faslodex (ICI 182,780)
a novel estrogen receptor downregulator: future possibilities in breast cancer, 209

PII: S0960-0760(01)00166-2

Fatty-acid metabolising enzymes
alternations in hepatic expression of, in ArKO mice and their reversal by treatment with 17β-estradiol or a peroxisome proliferator, 11

Germ cells
aromatase expression in male, 203

Human aorta
aromatase in atherosclerotic lesions of, 67

Letrozole
aromatase overexpression transgenic mice model: cell type specific expression and use of, to abrogate mammary hyperplasia without affecting normal physiology, 27

17α-Methyl testosterone
is a competitive inhibitor of aromatase activity in JAR choriocarcinoma cells and macrophage-like TH1 cells in culture, 239

Neoadjuvant therapy
biological and clinical effects of aromatase inhibitors in, 103
Nuclear receptor(s)
Regulation of aromatase by, 187

Placenta
identification of the regulatory regions of the human aromatase P450 (*CYP19*) gene involved in, -specific expression, 173
Protein kinase
regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated, 61

SERM (selective estrogen receptor modulators)
EM-652 (SCH57068) a pure, having complete antiestrogenic activity in the mammary gland and endometrium, 213
where do, and aromatase inhibitors now fit into breast cancer treatment algorithms? 227

Transgenic mice
tissue-specific expression of the human *CYP19* aromatase gene in ovary and adipose tissue of, 193

PERGAMON

Journal of Steroid Biochemistry & Molecular Biology 79 (2001) VIII–IX

The Journal of
Steroid Biochemistry
&
Molecular Biology

www.elsevier.com/locate/jsbmb

Author Index

Akira S., 11
Anderson E., 227
Anderson T.J., 103
Antich P.P., 49

Baillien M., 261
Ball G.F., 261
Balthazart J., 261
Bélanger A., 213
Benahmed M., 203
Berstein L.M., 157
Bhat A.S., 75
Bilinska B., 203
Blankenstein M.A., 41
Blijham G.H., 41
Boeddinghaus I.M., 85
Bourguiba S., 203
Britt K.L., 3, 181
Brodie A.M.H., 41
Brueggemeier R.W., 75
Bulun S.E., 19
Buzdar A.U., 109

Callard G.V., 305
Cameron D.A., 103
Carreau S., 203
Chen S., 35, 239
Chen T., 41
Chiang E.F.-l., 299
Chung B.-c., 299
Clark G.M., 157
Clarke R., 227
Conley A., 289
Constantinescu A., 49
Corbin C.J., 289

DeJong P.C., 41
Demers L.M., 157
Dixon J.M., 93, 103
Dowsett M., 85
Drummond A.E., 181
Dyson M., 181

Elbers J.R.J., 41
Eliza M., 239

Fang Z., 19
Findlay J.K., 181
Fulton A., 41
Fürbass R., 279

Galeraud-Denis I., 203
Genissel C., 203
Ghilchik M.W., 165
Giguère V., 213
Goss P.E., 143
Goto K., 187
Graham S., 289
Greger D., 289
Gurates B., 19

Hamilton C.J., 157
Harada N., 67, 151, 255
Hewitt K.N., 3
Hinshelwood M.M., 193
Hirasawa G., 49
Honda S.-i., 151
Honda S.-I., 255
Howell A., 227
Howell S.J., 227
Hsiao P.-H., 299

Inoue M., 61
Itoh T., 35

Jeng M.-H., 115
Jones M.E.E., 3, 181
Joomprabutra S., 75

Kalbe C., 279
Kamat A., 173
Kao Y.-C., 35
Kinoshita Y., 35
Kirma N., 27
Kishida M., 305

Labrie C., 213
Labrie F., 213
Lambard S., 203
Lawson J., 49
Leury B.J., 3
Levallet J., 203
Lønning P.E., 127
Long B.J., 41
Lu Q., 41

Macpherson N., 41
Mandava U., 27
Mapes S., 289
Masamura S., 115
Mason R.P., 49
Matsumoto T., 151, 255
McPherson R., 115
Mendelson C.R., 173, 193
Miller W.R., 93, 103
Misso M.L., 3
Mor G., 239
Mu Y.-M., 187
Murakami H., 67
Murakami K., 61

Naftolin F., 239
Nanu L., 49
Nawata H., 187
Nishi Y., 187
Nomura M., 187
Nortier J.W.R., 41

Okabe T., 187
Okada T., 11
Okubo T., 35
Onishi S., 11
Öz O.K., 3, 49

Parish D., 165
Parkey R.W., 49
Proietto J., 3
Purohit A., 165

Ragaz J., 133
Reed M.J., 165
Resko J.A., 247
Richards J.A., 75
Robertson J.F.R., 209
Robertson K.M., 3
Rosankiewicz J., 165
Roselli C.E., 247

Saibara T., 11
Said H.M., 279
Sakamoto H., 151
Santen R., 115
Santen R.J., 157
Santner S., 115
Sasano H., 67
Schipper M.E.I., 41
Schwerin M., 279
Sebastian S., 19

PII: S0960-0760(01)00193-5

Segawa T., 61
Shim W.-S., 115
Shizuta Y., 11
Shozu M., 61
Simard J., 213
Simpson E.R., 3, 49, 181
Singh A., 165
Slee P.H.T.J., 41
Song J., 239
Song R., 115
Strasser K., 143
Sumitani H., 61

Takayanagi R., 187
Takeda K., 11
Tamura M., 19
Tchoudakova A.V., 305
Tekmal R.R., 27
Thijssen J.H., 41
Thorburn A.W., 3
Toda K., 11
Tong S.-K., 299
Trant J., 289
Tremblay A., 213
Tremblay G., 213
Tsyganov E., 49

van de Ven J., 41
van Gorp J.M.H.H., 41
Vanselow J., 279

Walters K., 289
Wang J.-P., 115, 157
Whetstone J.L., 75
Wiita B., 239
Wood E., 305
Wreford N.G., 3, 181

Yanase T., 187
Yang C., 35
Yang H.-J., 61
Yang S., 19
Yao S., 3
Yoshimura N., 151
Yu B., 35
Yue W., 115, 157

Zerwekh J.E., 49
Zhou D., 35
Zhou J., 19
Zsolnai A., 279